|Treatment of MF-associated Anemia|
Srdan Verstovsek, MD, PhD
|Release Date: April 23, 2021|
Expiration Date: April 23, 2022
In this activity, Dr. Srdan Verstovsek will discuss management of myelofibrosis-associated anemia. He will provide guidance on thresholds for red blood cell transfusion, criteria for selecting anemia therapy, and current and emerging treatment options for managing anemia, including erythropoiesis-stimulating agents (ESAs), anabolic steroids, corticosteroids, immunomodulatory agents, Janus kinase (JAK) inhibitors, anti-hemojuvelin antibodies, ALK2 receptor inhibitors, and luspatercept.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Incyte Corporation.
|Begin, Earn CreditView Only, No Credit|